SCHEDULE: CVI Investments & Heights Capital Boost Aptevo Stake

CVI Investments and Heights Capital Management disclose a 9.9% beneficial ownership stake in Aptevo Therapeutics Inc. through warrants.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, 'Reporting Persons') have reported a beneficial ownership of 357,842 shares of Aptevo Therapeutics Inc. common stock.
• This ownership represents 9.9% of Aptevo Therapeutics Inc.'s outstanding common stock.
• The shares are issuable upon the exercise of warrants to purchase shares, with an exercise limitation preventing ownership from exceeding 9.99%.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and may exercise voting and dispositive power over the reported shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous disclosure of ownership.
• As of June 20, 2025, Aptevo Therapeutics Inc. had 3,224,156 shares outstanding, as per its Definitive Proxy Statement filed on July 3, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive institutional stake, which can be viewed as a vote of confidence in the company. While it's a disclosure and not a performance update, the presence of a large investor is generally a positive signal.

Positives

• A significant 9.9% stake by institutional investors CVI Investments and Heights Capital Management may signal confidence in Aptevo Therapeutics Inc.'s long-term prospects.
• The investment is structured through warrants, providing potential future capital infusion upon exercise.

Risks

• The warrants are not exercisable to the extent that beneficial ownership would exceed 9.99%, which could limit the Reporting Persons' ability to fully convert their holdings if the threshold is met.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Aptevo Therapeutics Inc. or the Reporting Persons regarding the company's future performance.

Industry Context

This filing reflects an institutional investment in a biotechnology company, a common occurrence in the sector where capital is often raised through various equity instruments, including warrants, to fund research and development or operational needs.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 9.9% stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: The presence of a large, passive investor may provide stability and a long-term perspective, though the filing explicitly states the investment is not for control purposes.

Key Dates

Recommendation

This filing is a disclosure of a passive ownership stake by institutional investors and does not provide operational or financial performance updates for Aptevo Therapeutics Inc. While a significant institutional stake can be a positive signal, it does not inherently change the fundamental investment thesis for the company. Investors should 'hold' and await further operational and financial disclosures to make a more informed decision.

Keywords

Aptevo Therapeutics, CVI Investments, Heights Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Biotechnology, Investment, Institutional Investor